Zepbound Prior Authorization 2026 Guide

Q: What BMI do I need to qualify for Zepbound?

Most commercial insurers require BMI >=30, or BMI >=27 with at least one weight-related comorbid condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. For the OSA indication, BMI >=30 is standard along with documented moderate-to-severe sleep apnea. Some Blue Cross Blue Shield affiliates have dropped GLP-1 weight-loss coverage entirely, so plan-specific verification matters.

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Zepbound prior authorization (PA) is the gate between a tirzepatide prescription and a covered fill at the pharmacy counter. Nearly every U.S. commercial plan requires it, the typical decision window runs 1–7 business days, and the single most common reason a PA stalls is incomplete documentation — not ineligibility. This guide covers what insurers actually want to see, how the obstructive sleep apnea (OSA) pathway differs from the weight-management pathway, what changed when CVS Caremark removed Zepbound from its standard commercial formulary on July 1, 2025, and what your appeal should contain if the first answer is no. It also explains where the PlexusDx Tirzepatide Injection Protocol ($249/mo) sits as a cash-pay bridge while a PA is pending or after a denial — because the practical question for most patients isn't whether to keep fighting the PA, it's how to avoid a coverage gap during the 1–6 weeks the process can take.

What Zepbound prior authorization actually is

Prior authorization is a coverage review, not a clinical rejection. Your insurer (or, more precisely, the pharmacy benefit manager that runs the drug-coverage side of your plan — CVS Caremark, Express Scripts, OptumRx, or one of several smaller PBMs) checks the prescription against a published criteria checklist before it will pay. The check happens because Zepbound's list price runs roughly $1,086 per month and plans want documented medical necessity. You cannot file the PA yourself — it goes from your prescriber's office to the PBM — but everything you bring to the appointment determines how cleanly the submission goes through. A complete first submission is the single biggest predictor of a fast approval. For patients cross-shopping cash-pay options in case the PA fails, the PlexusDx Tirzepatide Injection Protocol uses compounded tirzepatide at $249/mo with no PA required and shipping included.

What insurers require to approve Zepbound

The FDA-approved indications for Zepbound (tirzepatide) are chronic weight management in adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbid condition, alongside reduced-calorie diet and increased physical activity; and moderate-to-severe obstructive sleep apnea in adults with obesity (added December 2024). On top of the FDA baseline, most commercial insurers require: (1) a recent height/weight with calculated BMI and the matching ICD-10 diagnosis code; (2) documentation of at least one comorbidity if BMI is 27–29.9 — type 2 diabetes, hypertension, dyslipidemia, OSA, or established cardiovascular disease are the common qualifiers; (3) evidence of structured lifestyle modification (typically 3–6 months of documented diet, exercise, and behavioral effort); and (4) for many plans, step therapy — a documented prior trial of cheaper agents like phentermine, Contrave, Saxenda, or Wegovy. Some Blue Cross Blue Shield affiliates have stopped covering GLP-1s for weight loss entirely, so plan-specific verification matters before submission.

How long Zepbound PA takes — and what controls the speed

Typical clean submissions are decided in 1–7 business days. Electronic PA platforms (CoverMyMeds, Availity, Surescripts) can return same-day or next-day decisions when documentation is complete. ERISA rules — which govern most employer-sponsored plans — require a decision within 15 calendar days for standard pre-service requests and 72 hours for urgent requests, with a single allowable 15-day extension if the insurer flags missing information. The failure modes that turn a 7-day review into a 3-week review are missing data (no documented BMI history, no comorbidity ICD-10 code, no lifestyle-modification chart notes) and the wrong submission portal. Patient-side levers: prepare a one-page document with weight history, medication history, comorbidities, and lifestyle program participation before the appointment; respond within 24 hours to any insurer request for additional information; and ask the provider's office to confirm submission the same day.

The OSA pathway — different rules, often broader coverage

Since December 2024, Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. This matters because some commercial plans — and some Medicare Part D plans — that exclude anti-obesity medications entirely will still cover Zepbound when OSA is the primary indication. Typical OSA PA criteria look for AHI (apnea-hypopnea index) ≥15 documented by polysomnography or home sleep test, BMI ≥30, and CPAP intolerance or insufficient response. If your sleep study supports it, the OSA path is often the cleanest route to coverage on plans that won't write weight-loss claims — ICD-10 codes shift to G47.33, and the letter of medical necessity emphasizes the sleep-medicine clinical picture rather than the obesity framing.

CVS Caremark, Wegovy preference, and formulary exceptions

CVS Caremark removed Zepbound from its standard commercial formulary effective July 1, 2025; Wegovy (semaglutide) became the preferred GLP-1. If your plan is administered by CVS Caremark, three paths remain: switch to Wegovy (a different molecule — GLP-1 only rather than tirzepatide's GIP/GLP-1 dual action — but a real option many patients tolerate well); request a formulary exception for Zepbound with clinical justification (failed Wegovy, contraindication to semaglutide, or documented superior tirzepatide response); or step outside insurance to a self-pay route. Other PBMs may follow similar formulary moves at the next renewal cycle, so a Wegovy-vs-Zepbound formulary check is worth doing at every plan-year reset. If you'd rather keep tirzepatide and skip the formulary fight, the PlexusDx Tirzepatide Injection Protocol at $249/mo provides compounded tirzepatide with no PA and no step-therapy paperwork.

What to do if your Zepbound PA is denied

Denial is not the end of the road. KFF analysis of Medicare Advantage data found that only about 11% of denied prior authorizations are appealed — but when patients appeal, roughly 81% of denials are overturned. The appeal mechanics: read the denial letter carefully and identify the specific reason; have your prescriber draft a Letter of Medical Necessity that addresses each cited reason directly with chart-note evidence; gather missing supporting records (sleep study, prior medication trials with dates and doses, weight-loss program participation); and submit through the insurer's formal appeal channel within the deadline (typically 30–180 days). For ERISA plans, appeals must be decided within 30 days for pre-service determinations and 60 days for post-service, with a second-level external review available if the internal appeal fails. While the appeal moves through review — often 2–6 weeks — many patients use a cash-pay bridge to avoid restarting tirzepatide titration from scratch.

Cash-pay options — PlexusDx as the bridge

If the PA is pending, denied, or your plan dropped Zepbound from formulary, the cash-pay landscape has three meaningful options. Option one is Lilly Direct self-pay vials and KwikPen at roughly $349–$499/mo depending on dose — FDA-approved branded Zepbound, no PA, but only sold in single-dose vials and KwikPen formats. Option two is brand Zepbound at retail without insurance, around $1,086/mo at list price — rarely a serious cash-pay option. Option three is compounded tirzepatide through a licensed telehealth provider; the PlexusDx Tirzepatide Injection Protocol at $249/mo is the on-point cash-pay alternative, with weekly compounded tirzepatide across six dose levels (2.5mg to 15mg) and shipping included. Patients who want a daily oral form can use the Tirzepatide Oral Protocol ($279/mo); patients open to semaglutide while a Zepbound exception is reviewed can use Semaglutide Injection ($149/mo); and patients facing renewal-threshold issues at month 6 may benefit from the dual-compound GLP-Squared ($249/mo). Add the optional Precision Peptide Genetic Test ($298 standalone or $99 as a first-month add-on) to anchor titration to your GIPR rs1800437, GLP1R, FTO, and MC4R variants rather than starting from a population-average curve.

Frequently asked questions

Does Zepbound always need prior authorization?

For commercial insurance, almost always yes — PA is the standard for Zepbound across nearly every U.S. commercial plan due to its specialty status and list price. The only routes that bypass PA entirely are self-pay through Lilly Direct or compounded tirzepatide through a cash-pay telehealth provider like the PlexusDx Tirzepatide Injection Protocol at $249/mo.

How long does Zepbound prior authorization take?

Typically 1–7 business days from a complete submission, and as fast as 24 hours when the documentation is clean and the PA is filed electronically. ERISA-governed plans must decide within 15 calendar days for standard requests and 72 hours for urgent requests; missing documentation can push the decision to two weeks or longer.

What BMI do I need to qualify for Zepbound?

Most commercial insurers require BMI ≥30, or BMI ≥27 with at least one weight-related comorbid condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. For the OSA indication, BMI ≥30 is standard along with documented moderate-to-severe sleep apnea. Some Blue Cross Blue Shield affiliates have dropped GLP-1 weight-loss coverage entirely, so plan-specific verification matters.

What changed with CVS Caremark and Zepbound?

CVS Caremark removed Zepbound from its standard commercial formulary effective July 1, 2025, naming Wegovy as the preferred GLP-1. Patients on CVS Caremark plans can switch to Wegovy, request a formulary exception with clinical justification, or move to a cash-pay route — the PlexusDx Tirzepatide Injection Protocol at $249/mo is the on-point cash-pay tirzepatide option.

What does step therapy mean for Zepbound?

Step therapy means the insurer requires documented prior trials of cheaper weight-loss medications — commonly phentermine, Contrave, Saxenda, or Wegovy — before approving Zepbound. If you've already tried and failed alternative medications, make sure the dates, doses, durations, and outcomes are clearly documented in your chart so the PA submission can reference them.

What goes in a strong Letter of Medical Necessity?

A Letter of Medical Necessity should state the specific diagnosis with ICD-10 codes, prior treatment history with dates and outcomes, why alternatives are not appropriate (contraindications, intolerance, or insufficient response), and the expected clinical benefit of Zepbound specifically. Lilly publishes a downloadable LMN template for prescribers, and a thorough letter measurably improves both first-submission approval rates and appeal-stage overturn rates.

What are my cash-pay options if the PA is denied?

The three practical cash-pay routes are Lilly Direct self-pay (FDA-approved Zepbound vials and KwikPen, roughly $349–$499/mo depending on dose), retail pharmacy without insurance (about $1,086/mo at list price — rarely viable), and compounded tirzepatide through a licensed telehealth provider. The PlexusDx Tirzepatide Injection Protocol at $249/mo is the cash-pay tirzepatide option and works as either a bridge during an appeal or a permanent alternative.

Zepbound Prior Authorization (2026): Criteria, Timelines, and What to Do While You Wait | PlexusDx